New agents for treatment of systemic fungal infections

Expert Opinion on Emerging Drugs

Volumn 5, Issue 2, 2000, Pages 135-160

  Arikan, Sevtap ^a   Rex, John H ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

amphotericin B; amphotericin B colloidal dispersion; amphotericin B lipid complex; antifungal peptide; caspofungin; FK463; fluconazole; itraconazole; ketoconazole; liposomal amphotericin B; liposomal nystatin; posaconazole; ravuconazole; sordarin; VER 002; voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; NYSTATIN; POSACONAZOLE; RAVUCONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

DRUG FORMULATION; DRUG MECHANISM; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TOXICITY; EDEMA; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; LIVER TOXICITY; MYCOSIS; NAUSEA; REVIEW; VOMITING;

EID: 0033922629     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.5.2.135     Document Type: Review

References (223)

1. WINGARD J: Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy. Clin. Infect. Dis. (1994) 19:S49-S53. (Pubitemid 24258974)
2. ANAISSIE E, BODEY GP, KANTARJIAN H et al.: New spectrum of fungal infections in patients with cancer. Rev. Infect. Dis. (1989) 11:369-378.
3. PATEL R, PORTELA D, BADLEY AD et al.: Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation (1996) 62:926-934. (Pubitemid 26360353)
4. HIEMENZ JW, WALSH TJ: Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. (1996) 22:S133-S144. (Pubitemid 26256445)
5. KORTING HC, SCHAFER-KORTING M, ZIENICKE H, GEORGII A, OLLERT MW: Treatment of tinea unguium with medium and high doses of ultramicrosize griseo-fulvin compared with that with itraconazole. Antimi-crob. Agents Chemother. (1993) 37:2064-2068. (Pubitemid 23298190)
6. HIEMENZ JW, WALSH TJ: Lipid formulations of amphotericin B. J. Liposome Res. (1998) 8:443-467. (Pubitemid 29001654)
7. TERRELL CL, HUGHES CE: Antifungal agents used for deep-seated mycotic infections. Mayo. Clin. Proc. (1992) 67:69-91.
8. WALSH TJ, MELCHER GP, RINALDI MG et al.: Tricho-sporon beigelii, an emerging pathogen resistant to amphotericin B. J. Clin. Microbiol. (1990) 28:1616-1622. (Pubitemid 20212896)
9. GUEHO E, SMITH MT, DE HOOG GS et al.: Contributions to a revision of the genus Trichosporon. Antonie van Leeuwenhoek (1992) 61:289-316.
10. SUTTON DA, SANCHE SE, REVANKAR SG, FOTHERGILL AW, RINALDI MG: In vitro amphotericinB resistance in clinical isolates of Aspergillus terreus, with head-to-head comparison to voriconazole. J. Clin. Microbiol. (1999) 37:2343-2345. (Pubitemid 29277804)
11. WALSH M, WHITE L, ATKINSON K, ENNO A: Fungal Pseudallescheria boydii lung infiltrates unresponsive to amphotericin B in leukaemic patients. Aust. NZ J. Med. (1992) 22:265-268.
12. FRANCIS P, WALSH TJ: Approaches to management of fungal infections in cancer patients. Oncology (1992) 6:133-144.
13. ARIKAN S, LOZANO-CHIU M, PAETZNICK V, NANGIA S, REX JH: Microdilution susceptibility testing of amphotericin B, itraconazole and voriconazole against clinical isolates of Aspergillus and Fusarium species. J. Clin. Microbiol. (1999) 37:3946-3951.
14. KARYOTAKIS NC, ANAISSIE EJ, HACHEM R, DIGNANI MC, SAMONIS G: Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice. J. Infect. Dis. (1993) 168:1311-1313. (Pubitemid 23317159)
15. KARYOTAKIS NC, ANAISSIE EJ: Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection inneutropenic mice. Antimi-crob. Agents Chemother. (1994) 38:2660-2662. (Pubitemid 24332604)
16. SABRA R, BRANCH RA: Mechanisms of amphotericin B-induced decrease in glomerular filtration rate in rats. Antimicrob. Agents Chemother. (1991) 35:2509-2514.
17. MEYER RD: Current role of therapy with amphotericin B. Clin. Infect. Dis. (1992) 14 (Suppl. 1):S154-S160.
18. JANKNEGT R, DE MARIE S, BAKKER-WOUDENBERG IA, CROMMELIN DJ: Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin. Pharmacokin. (1992) 23:279-291.
19. ANAISSIE EJ, MATTIUZZI GN, MILLER CBet al.: Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Antimicrob. Agents Chemother. (1998) 42:606-611. (Pubitemid 28114816)
20. OLDFIELD EC, 3rd, GARST PD, HOSTETTLER C, WHITE M, SAMUELSON D: Randomized, double-blind trial of 1-versus 4-hour amphotericin B infusion durations. Antimicrob. Agents Chemother. (1990) 34:1402-1406. (Pubitemid 20215783)
21. STORM G, VAN ETTEN E: Biopharmaceutical aspects of lipid formulations of amphotericin B. Eur. J. Clin. Microbiol. Infect. Dis. (1997) 16:64-73. (Pubitemid 27095987)
22. SHEEHAN DJ, HITCHCOCK CA, SIBLEY CM: Current and emerging azole antifungal agents. Clin. Microbiol. Rev. (1999) 12:40-79. (Pubitemid 29055953)
23. GHANNOUM MA, REX JH, GALGIANI JN: Susceptibility testing of fungi: Current status of the correlation of in vitro data with clinical outcome. J. Clin. Microbiol. (1996) 34:489-495. (Pubitemid 26065761)
24. ARIKAN S, AKOVA M, HAYRAN M et al.: Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidia-sis. Clin. Infect. Dis. (1998) 26:903-908. (Pubitemid 28180327)
25. WONG-BERINGER A, JACOBS RA, GUGLIELMO BJ: Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. (1998) 27:603-618. (Pubitemid 28422013)
26. LEENDERS ACAP, DE MARIE S: The use of lipid formula-tionsof amphotericinBfor systemic fungal infections. Leukemia (1996) 10:1570-1575. (Pubitemid 26333810)
27. HIEMENZ JW, LISTER J, ANAISSIE E: Emergency use amphotericin Blipid complex (ABLC)inthe treatment of patients with aspergillosis: historical control comparison with amphotericin B. Blood (1995) 86(Suppl. 1):849a.
28. JANOFF AS, PERKINS WR, SALETON SL, SWENSON CE: Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B-related toxicities. J. Liposome Res. (1993) 3:451-472.
29. OLSEN SJ, SWERDEL MR, BLUE B, CLARK JM, BONNER DP: Tissue distributionofamphotericinBlipid complex in laboratory animals. J. Pharmacol. (1991) 43:831-835.
30. LISTER J: Amphotericin B lipid complex (Abelcet) in the treatment of invasive mycoses: the North American experience. Eur. J. Haematol. (1996) 56:18S-23S.
31. GARNACHO-MONTERO J, ORTIZ-LEYBA C, GARMENDIA JLG, JIMENEZ FJJ: Life-threatening adverse event after amphoterin B lipid complex treatment in a patient treated previously with amphoterin B deoxycholate. Clin. Infect. Dis. (1998) 26:1016. (Pubitemid 28180363)
32. WINGARD JR: EfficacyofamphotericinBlipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant. (1997) 19:343-347. (Pubitemid 27096066)
33. GUO LSS, FIELDING RM, LASIC DD: Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs. Int. J. Pharm. (1991) 75:45-54.
34. OPPENHEIM BA, HERBRECHTR, KUSNE S:Thesafety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin. Infect. Dis. (1995) 21:1145-1153.
35. WHITE MH, BOWDEN RA, SANDLER E et al.: Amphotericin B colloidal dispersion vs. amphotericin B in the empiric treatment of febrile neutropenic patients. Blood (1996) 88(Suppl. 1):302a.
36. PATEL R: Amphotericin B colloidal dispersion. Exp. Opin. Pharmacother. (2000) 1(3):475-488.
37. WORKING PK: Amphotericin B colloidal dispersion Pre-clinical review. Chemotherapy (1999) 45(Suppl. 1):15-26. (Pubitemid 29308657)
38. WHITE MH, ANAISSIE EJ, KUSNE S et al.: Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin. Infect. Dis. (1997) 24:635-642. (Pubitemid 27143557)
39. VALERO G, GRAYBILL JR: Successful treatment of Cryptococcal meningitis with amphotericin B colloidal dispersion: report of four cases. Antimicrob. Agents Chemother. (1995) 39:2588-2590.
40. WHITE MH, BOWDEN RA, SANDLER ES et al.: Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin. Infect. Dis. (1998) 27:296-302. (Pubitemid 28365752)
41. JOHNSON JR, KANGAS PJ, WEST M: Serious adverse event after unrecognized substitution of one amphotericin B lipid preparation for another. Clin. Infect. Dis. (1998) 27:1342-1343. (Pubitemid 29242511)
42. ADLER-MOORE JP, PROFFITT RT: Development, characterization, efficacy and mode of actionof AmBisome, a unilamellar liposomal formulationof amphotericin B. J. Liposome Res. (1993) 3:429-450. (Pubitemid 24007409)
43. LEE JW, AMANTEA MA, FRANCIS PA: Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob. Agents Chemother. (1994) 38:713-718. (Pubitemid 24114006)
44. PROFFITT RT, SATORIUS A, CHIANG SM, SULLIVAN L, ADLER-MOORE JP: Pharmacology and toxicology of a liposomal formulationofamphotericinB(AmBisome) in rodents. J. Antimicrob. Chemother. (1991) 28(Suppl. B):49-61.
45. GROLLA, GIRI N,GONZALEZ Cet al.: Penetrationof lipid formulations of amphotericin B into cerebrospinal fluid and brain tissue. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract A-90.
46. FRANCIS P, LEE JW, HOFFMAN A et al.: Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocy-topenic rabbits: the potential role of bronchoalveolar lavage D-mannitol and galactomannan as markers of infection. J. Infect. Dis. (1994) 169:356-368.
47. ELLIS M, SPENCE D, DE PAUW Bet al.: AnEORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatmentof invasive aspergillosis. Clin. Infect. Dis. (1998) 27:1406-1412. (Pubitemid 29242412)
48. WALSH TJ, YELDANDI V, MCEVOY M et al.: Safety, tolerance and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob. Agents Chemother. (1998) 42:2391-2398. (Pubitemid 28420384)
49. TOLLEMAR J, RINGDEN O, ANDERSSON S et al.: Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant. (1993) 12:577-582. (Pubitemid 24020989)
50. LAING RBS, MILNE LJR, LEEN CLS, MALCOM GP, STEERS AJ: Anaphylactic reactions to liposomal amphotericin. Lancet (1994) 344:682.
51. TORRE I, LOPEZ-HERCE J, VAZQUEZ P: Anaphylactic reaction to liposomal amphotericin B in children. Ann. Pharmacother. (1996) 30:1037-1038.
52. AYESTARAN A, LOPEZ RM, MONTORO JB et al.: Pharma-cokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia. Antimicrob. Agents Chemother. (1996) 40:609-612. (Pubitemid 26075429)
53. CAILLOT D, CHAVANET P, CASANOVAS O et al.: Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. Eur. J. Clin. Microbiol. Infect. Dis. (1992) 11:722-725.
54. SORKINE P, NAGAR H, WEINBROUM A et al.: Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients. Crit. Care Med. (1996) 24:1311-1315. (Pubitemid 26262403)
55. SCHOFFSKI P, FREUND M, WUNDER R et al.: Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. Br. Med. J. (1998) 317:379-384. (Pubitemid 28359309)
56. TORRE D, BANFI G, TAMBINI R et al.: A retrospective study on the efficacy and safety of amphotericin B in a lipid emulsion for the treatment of Cryptococcal meningitis in AIDS patients. J. Infect. (1998) 37:36-38. (Pubitemid 28421201)
57. BARQUIST E, FEIN E, SHADICK D, JOHNSON J, CLARK J, SHATZ D: A randomized prospective trial of amphotericin B lipid emulsion versus dextrose colloidal solution in critically ill patients. J. Trauma (1999) 47:336-340. (Pubitemid 29387769)
58. MOREAU P, MILPIED N, FAYETTE N, RAME JF, HAROUS-SEAU JL: Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J. Antimicrob. Chemother. (1992) 30:535-541.
59. NUCCI M, LOUREIRO M, SILVEIRA F et al.: Comparison of the toxicityofamphotericinBin5%dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients.Antimicrob. Agents Chemother. (1999) 43:1445-1448. (Pubitemid 29259341)
60. ANDERSON RP, CLARK DA: Amphotericin B toxicity reduced by administration in fat emulsion. Ann. Pharmacother. (1995) 29:496-500.
61. GALES MA, GALES BJ, ALFORD KM: Acute renal failure with amphotericinBinlipid emulsion.Ann. Pharmaco-ther. (1996) 30:1036. (Pubitemid 26295262)
62. ERICSSON O, HALLMEN A-C, WIKSTROM I: Amphotericin B is incompatible with lipid emulsions. Ann. Pharmacother. (1996) 30:298.
63. TRISSEL LA: Amphotericin B does not mix with fat emulsion. Am. J. Health-System Pharm. (1995) 52:1463-1464.
64. WALKER S, TAILOR SAN, LEE M et al.: Amphotericin B in lipid emulsions: Stability, compatibility and in vitro antifungal activity. Antimicrob. Agents Chemother. (1998) 42:762-766. (Pubitemid 28216350)
65. OWENS D, FLEMING RA, RESTINO MS, CRUZ JM, HURD DD: Stability of amphotericin B 0.05 and 0.5 mg/ml in 20% fat emulsion. Am. J. Health-System Pharm. (1997) 54:683-686. (Pubitemid 27136668)
66. CLEARY JD: Amphotericin B formulated in a lipid emulsion. Ann. Pharmacother. (1996) 30:409-412. (Pubitemid 26111076)
67. ODDS FC, CHEESMAN SL, ABBOTT AB: Antifungal effects offluconazole (UK 49858),anew triazoleantifungal,in vitro. J. Antimicrob. Chemother. (1986) 18:473-478. (Pubitemid 16030724)
68. MARRIOTT MS, RICHARDSON K: The discovery and mode of action of fluconazole. In: Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Fromtling RA (Ed.), JR Prous Science Publishers, Barcelona, Spain (1987):81-92.
69. LYMAN CA, WALSH TJ: Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs (1992) 44:9-35.
70. COMO JA, DISMUKES WE: Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med. (1994) 330:263-272. (Pubitemid 24034139)
71. ANAISSIE EJ, KONTONYIANNIS DP, HULS C et al.: Safety, plasma concentrations and efficacy of high-dose fluconazole in invasive mold infections. J. Infect. Dis. (1995) 172:599-602.
72. BERRY AJ, RINALDI MG, GRAYBILL JR: Use of high-dose fluconazole as salvage therapy for Cryptococcal meningitis in patients with AIDS. Antimicrob. Agents Chemother. (1992) 36:690-692.
73. HAUBRICH RH, HAGHIGHAT D, BOZZETTE SA, TILLES J, MCCUTCHAN JA, THE CALIFORNIA COLLABORATIVE TREATMENT GROUP: High-dose fluconazole for treatment of Cryptococcal disease in patients with human immunodeficiency virus infection. J. Infect. Dis. (1994) 170:238-242. (Pubitemid 24186455)
74. MENICHETTI F, FIORIO M, TOSTI A et al.: High-dose fluconazole therapy for Cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. (1996) 22:838-840. (Pubitemid 26255605)
75. GALGIANI JN: Coccidioidomycosis. West. J. Med. (1993) 159:153-171. (Pubitemid 23237612)
76. WHEAT J, MAWHINNEY S, HAFNER R et al.: Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. Am. J. Med. (1997) 103:223-232. (Pubitemid 27413405)
77. PAPPAS PG, BRADSHER RW, KAUFFMAN CA et al.: Treatment of blastomycosis with higher doses of fluconazole. Clin. Infect. Dis. (1997) 25:200-205. (Pubitemid 27364714)
78. KAUFFMAN CA, PAPPAS PG, MCKINSEY DS et al.: Treatment of lymphocutaneous and visceral sporotri-chosis with fluconazole. Clin. Infect. Dis. (1996) 22:46-50. (Pubitemid 26022011)
79. REX JH, PFALLER MA, GALGIANI, JN et al.: Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itracona-zole and Candida infections. Clin. Infect. Dis. (1997) 24:235-247. (Pubitemid 127774263)
80. PFALLER MA, MESSER SA, HOLLIS RJ et al.: Trends in species distribution and susceptibility to fluconazole among blood stream isolates ofCandida speciesin the United States. Diagn. Microbiol. Infect. Dis. (1999) 33:217-222. (Pubitemid 29142360)
81. REX JH, RINALDI MG, PFALLER MA: Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother.(1995) 39:1-8.
82. DENNING DW, HANSON LH, PERLMAN AM, STEVENS DA: In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn. Microbiol. Infect. Dis. (1992) 15:21-34.
83. DEBRUYNE D, RYCKELYNCK JP: Clinical pharmacoki-netics of fluconazole. Clin. Pharmacokinet. (1993) 24:10-27.
84. MALIK IA, MOID I, AZIZ Z, KHAN S, SULEMAN M: A randomized comparison of fluconazole with amphotericin B as empiric antifungal agentsin cancer patients with prolonged fever and neutropenia. Am. J. Med. (1998) 105:478-483. (Pubitemid 29013332)
85. ABBOTT M, HUGHES DL, PATEL R, KINGHORN GR: Angio-oedema after fluconazole. Lancet (1991) 338:633.
86. AGARWAL A, SAKHAJA V, CHUGH KS: Fluconazole-induced thrombocytopenia. Ann. Intern. Med. (1990) 113:899.
87. PAPPAS PG, KAUFFMAN CA, PERFECT J et al.: Alopecia associated with fluconazole therapy. Ann. Intern. Med. (1995) 123:354-357.
88. BOOGAERTS J, MICHAUX J-L, BOSLY A et al.: Pharma-cokinetics and safety of seven daysof intravenous (IV) itraconazole followed by two weeks oral itraconazole solution in patients with haematological malignancy. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, USA 1996) Abstract A-87.
89. VANDEWOUDE K, VOGELAERS D, DECRUYENAERE J et al.: Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob. Agents Chemother. (1997) 41:2714-2718. (Pubitemid 27524745)
90. ZHOU HH, GOLDMAN M, WU J et al.: A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J. Clin. Pharmacol. (1998) 38:593-602. (Pubitemid 28354896)
91. BAILEY EM, KRAKOVSKY DJ, RYBAK MJ: The triazole antifungal agents: a review of itraconazole and fluconazole. Pharmacotherapy (1990) 10:146-153. (Pubitemid 20149608)
92. WILDFEUER A, SEIDL HP, PAULE I, HABERREITER A: In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses (1998) 41:309-319. (Pubitemid 28553052)
93. UZUN O, ARIKAN S, KOCAGÖZ S, SANCAK B, UNAL S: In vitro activity of voriconazole compared with flucona-zole, itraconazole and amphotericin B against Candida isolated in a Turkish University hospital. 21st International Congress of Chemotherapy. Birmingham, UK (1999) Abstract P47.
94. NGUYEN MH, YU CY: Voriconazole against fluconazole-susceptible and resistant Candida isolates: in vitro efficacy compared with that of itraconazole and ketoconazole. J. Antimicrob. Chemother. (1998) 42:253-256. (Pubitemid 28393597)
95. MCGINNIS MR, PASARELL L, SUTTON DA et al.: In vitro activity of voriconazole against selected fungi. Med. Mycol. (1998) 36:239-242.
96. MENICHETTI F, DEL FAVERO A, MARTINO P et al.: Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin. Infect. Dis. (1999) 28:250-255. (Pubitemid 29241212)
97. MICHALLET M, PERSAT F, KRANZHOFER N et al.: Pharma-cokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. Bone Marrow Transplant. (1998) 21:1239-1243. (Pubitemid 28318752)
98. MEUNIER F: Future directions of antimycotic therapy. Mycoses (1994) 37:77-82.
99. DENNING DW, TUCKER RM, HANSON LH, STEVENS DA: Treatment of invasive aspergillosis with itraconazole. Am. J. Med. (1989) 86:791-800. (Pubitemid 19148096)
100. SCHOLER HJ: Flucytosine. In: Antifungal Chemotherapy. Speller DCE (Ed.), Wiley & Sons, Chichester, UK (1980):35-106.
101. VAN DER HORST C, SAAG M, CLOUD G et al.: Part 1. Randomized double blind comparison of amphotericin B plus flucytosine to amphotericin B alone (Step 1) Followed by a comparison of flucona-zole to itraconazole (Step 2) in the treatment of acute Cryptococcal meningitis in patients with AIDS. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995) Abstract 1216.
102. SAAG M, VAN DER HORST C, CLOUD G et al.: Part 2. Randomized double blind comparison of amphotericin B plus flucytosine to amphotericin B alone (Step 1) Followed by a comparison of flucona-zole to itraconazole (Step 2) in the treatment of acute Cryptococcal meningitis in patients with AIDS. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995) Abstract 1217.
103. WHELAN WL: The genetic basis of resistance to 5-fluorocytosine in Candida species and Crypto-coccus neoformans. Crit. Rev. Microbiol. (1987) 15:45-56.
104. MAYANJA-KIZZA H, OISHI K, MITARAIS et al.: Combination therapy with fluconazole and flucytosine for Cryptococcal meningitis in Ugandan patients with AIDS. Clin. Infect. Dis. (1998) 26:1362-1366.
105. DIAMOND DM, BAUER M, DANIEL BE et al.: Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine Cryptococcal meningitis. Antimicrob. Agents Chemother. (1998) 42:528-533. (Pubitemid 28114803)
106. JUST-NÜBLING G, HEISE W, RIEG G et al.: Triple combination of amphotericin B, flucytosine and fluconazole for treatment of acute Cryptococcal meningitis in patients with AIDS. 3rd International Conference on Cryptococcus and Cryptococcosis. Paris, France (1996) Abstract V5.
107. DENNING DW: Treatment of invasive aspergillosis. J. Infect. (1994) 28(Suppl. 1):25-33.
108. YOON SA, VAZQUES JA, STEFFAN PE, SOBEL J, AKINS RA: High frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimi-crob. Agents Chemother. (1999) 43:836-845. (Pubitemid 29165746)
109. BOKEN DJ, SWINDELLS S, RINALDI MG: Fluconazole-resistant Candida albicans. Clin. Infect. Dis. (1993) 17:1018-1021. (Pubitemid 23358748)
110. REX J, LOZANO-CHIU M, PAETZNICK V et al.: Suscepti bility testing of current Candida bloodstream isolates from Mycoses Study Group (MSG) collaborative study #34: Isolates of Candida krusei are often resistant to both fluconazole and amphotericin B. 36th Annual Meeting of the Infectious Diseases Society of America. Denver, USA (1998) Abstract 324
111. YAMAMOTO Y, KLEIN TW, FRIEDMAN H, KIMURA S, YAMAGUCHI H: Granulocyte colony-stimulating factor potentiates anti-Candida albicans growth inhibitory activity of polymorphonuclear cells. FEMS Immunol Med. Microbiol. (1993) 7:15-22 (Pubitemid 23204353)
112. ROILIDES E, HOLMES A, BLAKE C et al.: Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: enhancement by granulocyte-macrophage colony-stimulating factor and interferon-y. J. Infect. Dis. (1994) 170:894-899 (Pubitemid 24296569)
113. DENNING DW: Echinocandins and pneumocandins-a new antifungal class with a novel mode of action. J. Antimicrob. Chemother. (1997) 40:611-614 (Pubitemid 27503990)
114. GEORGOPAPADAKOU NH: Antifungals: mechanism of action and resistance, established and novel drugs. Curr. Opin. Microbiol. (1998) 1:547-557 (Pubitemid 128433642)
115. DENNING DW: Invasive aspergillosis in immunocompromised patients. Curr. Opin. Infect. Dis. (1994) 7:456-462 (Pubitemid 24251313)
116. BODEY GP: Infection in cancer patients: a continuing association. Am. J. Med. (1986) 81:11-26 (Pubitemid 16054011)
117. MEADE RH: Drug therapy reviews: clinical pharma cology and therapeutic use of antimycotic drugs. Am. J Hosp. Pharm. (1979) 36:1326-1334
118. MEHTA RT, HOPFER RL, GUNNER LA, JULIANO RL, LOPEZ-BERESTEIN G: Formulation, toxicity and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob. Agents Chemother. (1987) 31:1897-1900 (Pubitemid 18009557)
119. JESSUP CJ, WALLACE TJ, GHANNOUM MA: Evaluation of antifungal activity of Nyotran against various pathogenic fungi. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F-88.
120. WALLACE TL, PAETZNICK V, COSSUM PA et al.: Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob Agents Chemother. (1997) 41:2238-2243 (Pubitemid 27422219)
121. ARIKAN S, LOZANO-CHIU M, PAETZNICK V etal.:In vitro activity of liposomal nystatin compared with amphotericin B and fluconazole against clinical Candida isolates. 98th General Meeting of the American Society for Microbiology. Atlanta, USA (1998) Abstract C-280
122. CARILLO-MUNOZ AJ, QUINDOS G, TUR C et al.: In vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericinBcholesteryl sulphate, liposomal amphotericin B, amphotericin Blipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. J. Antimicrob. Chemother. (1999) 44:397-401. (Pubitemid 29425694)
123. MEHTA RT, HAYMAN A, SARIN P, LOPEZ-BERESTEIN G: AR-121. Drugs Future (1994) 19:724-730.
124. MEHTA RT, HOPFER RL, MCQUEEN T, JULIANO RL, LOPEZ-BERESTEIN G. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob. Agents Chemother. (1987) 31:1901-1903. (Pubitemid 18009558)
125. DENNING DW, WARN P: Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B. Antimicrob. Agents Chemother. (1999) 43:2592-2599. (Pubitemid 29519535)
126. ROLSTON K, BAIRD I, GRAHAM DR, JAUREGUI L: Treatment of refractory episodes of candidemia in non-neutropenic patients with liposomal nystatin (Nyotran). 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998) Abstract LB-1.
127. RIOS A, ROSENBLUM M, CROFOOT G et al.: Pharmacoki-netics of liposomal nystatin in patients with human immunodeficiency virus infection. J. Infect. Dis. (1993) 168:253-254. (Pubitemid 23178769)
128. POWLES R, MAWHORTER S, WILLIAMS T: Liposomal nystatin (Nyotran) vs. amphotericin B (Fungizone) in empiric treatment of presumed fungal infection in neutropenic patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1999) Abstract LB-4.
129. WILLIAMS AH, MOORE JE: Multicenter study to evaluate the safety and efficacy of various doses of liposome-encapsulated nystatin in non-neutropenic patients with candidemia. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1999) Abstract J-1420.
130. KURTZ M, REX J: Glucan synthase inhibitors as antifungal agents. In: Advances in Protein Chemistry. Scolnick E (Ed.), (2000). (In Press).
131. COPLEY-MERRIMAN CR, RANSBURG NJ, CRANE LR et al.: Cilofungin treatment of Candida esophagitis: preliminary Phase II results. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, USA (1990) Abstract 581.
132. COPLEY-MERRIMAN CR, GALLIS H, GRAYBILL JR, DOEBBELING BN, HYSLOP DL: Cilofungin treatment of disseminated candidiasis: preliminary Phase II results. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, USA (1990) Abstract 582
133. KURTZ MB, HEATH IB, MARRINAN J et al.: Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-|3-D-glucan synthase. Antimicrob. Agents Chemother. (1994) 38:1480-1489 (Pubitemid 24203556)
134. ARIKAN S, LOZANO-CHIU M, PAETZNICK V, REX JH: In vitro susceptibility testing methods for caspofungin (CAS) against Aspergillus (ASP) and Fusarium (FUS) isolates. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1999) Abstract J-160
135. DE LUCCA AJ, WALSH TJ: Antifungal peptides: novel therapeutic compounds against emerging pathogens. Antimicrob. Agents Chemother. (1999) 43:1-11 (Pubitemid 29069190)
136. MEULBROEK J, OLEKSIJEW A, TOVCIMAK A et al.: Efficacy of A-175800.0, an inhibitor of fungal cell wall synthesis, against experimental systemic candidiasis. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F-82
137. IWAMOTO T, FUJI EA, NITT AK et al.: WF11899 A,B and C, novel antifungal lipopeptides. II. Biological properties.J. Antibiotics (1994) 47:1092-1097 (Pubitemid 24351557)
138. IWAMOTO T, FUJIE A, SAKAMOTO K et al.: WF11899A, B and C, novel antifungal lipopeptides. I. Taxonomy, fermentation, isolation and physico-chemical properties. J. Antibiotics (1994) 47:1084-1091 (Pubitemid 24351556)
139. HAWSER S, BORGONOVI M, MARKUS A, ISERT D Mulundoncandins, an echinocandin-like lipopeptide antifungal agent: biological activities in vitro. J Antibiotics (1999) 52:305-310 (Pubitemid 29160987)
140. DOMINGUEZ JM, KELLY VA, KINSMAN OS et al.: Sordarins: a new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts. Antimicrob. Agents Chemother. (1998) 42:2274-2278. (Pubitemid 28420363)
141. DOMINGUEZ JM, CAPA L, SERRAMIA MJ et al: Translation elongation factor 2 (EF2) is the target for sordarin-derived antifungals. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F-55
142. HERREROS E, MARTINEZ A, JIMENEZ E et al.: Anti-pneumocystosis activity of GM 237354 in vitro andin vivo. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F-64
143. BUENO JM, CHICHARRO J, HUSS SI, FIANDORJM, GOMEZ DES LAS HERAS F: Synthesis of the antifungal GM 237354. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F-54
144. HERREROS E, MARTINEZ CM, ALMELA MJ et al.: Sordarins: In vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii and filamentous fungi. Antimicrob. Agents Chemother. (1998) 42:2863-2869. (Pubitemid 28501217)
145. AVILES P, PATEMAN A, SAN ROMAN R, GARGALLO D: Single-dose pharmacokinetic studies in rodents with GM237354, a new systemic antifungal agent. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F-66.
146. SANCHEZ-SOUSA A, ALVAREZ ME A, PARRA C, BAQUERO F: Activity on clinical yeast isolates of a new antifungal agent, GM 237354. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F-56.
147. HERREROS E, MARTINEZ CM, ALMELA MJ et al.: In vitro activity of GM 237354 against a broad range of fungi. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F-57.
148. STEVENS DA: Screening of sordaricin derivatives against endemic fungal pathogens. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F-58.
149. ALIOUAT EM, AVILES P, DEI-CAS E et al.: In vitropharma-codynamic parameters of sordarin derivatives in comparison with marketed compounds against rat-derived Pneumocystis carinii. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998) Abstract J-15.
150. ALVAREZ ME, HERREROS E, SANCHEZ-SOUSA A, GARGALLO-VIOLA D, BAQUERO F: In vitro activity of sordarins in combination with other systemic antifungal agents
151. CAPA L, MENDOZA A, LAVANDERA JL, GOMEZ DE LAS HERAS F, GARCIA-BUSTOS JF: Translation elongation factor 2 is part of the target for a new family of antifun-gals. Antimicrob. Agents Chemother. (1998) 42:2694-2699. (Pubitemid 28462917)
152. MARTINEZ A, JIMINEZ E, AVILES P et al.: Antifungal activity of sordarin derivatives against fluconazole-susceptible and-resistant Candida albicans. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1999) Abstract J-294.
153. MARTINEZ A, FERRER S, JIMENEZ E et al.: Antifungal activity of sordarin derivatives against non-lethal models of candidiasis in rats. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1999) Abstract J-1999.
154. GRAYBILL JR, NAJVAR L, FOTHERGILL A, BOCANEGRA R, GOMEZ DE LAS HERAS F: Activities of sordarins in murine histoplasmosis. Antimicrob. Agents Chemother. (1999) 43:1716-1718. (Pubitemid 29331253)
155. AVILES P, ALIOUAT EM, MARTINEZ A et al.: Pharmacoki-netic/pharmacodynamic (PK/PD) study of sordarin derivatives against Pneumocystis carinii pneumonia. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998) Abstract J-56.
156. GATEHOUSE DG, WILLIAMS TC, SULLIVAN AT et al.: Sordarins: toxicological evaluation and safety pharmacology in rats and dogs. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998) Abstract J-75.
157. ESPINEL-INGROFF A: In vitro activities of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. (1998) 36:198-202. (Pubitemid 28047458)
158. CLANCY CJ, NGUYEN MH: In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur. J. Clin. Microbiol. Infect. Dis. (1998) 17:573-575. (Pubitemid 28464363)
159. LOZANO-CHIU M, ARIKAN S, PAETZNICK VL, ANAISSIE EJ, REX JH: Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species ofCandidaand level offlucona-zole susceptibility. J. Clin. Microbiol. (1999) 37:2755-2759. (Pubitemid 29391882)
160. JOHNSON EM, SZEKELY A, WARNOCK DW: In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J. Antimi-crob. Chemother. (1998) 42:741-745. (Pubitemid 29008075)
161. TROKE PF, BRAMMER KW, HITCHCOCK CA, YONREN S, SARANTIS N: UK-109,496, a novel, wide spectrum triazole derivative for the treatment of fungal infections: activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candidiasis. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995) Abstract F-73.
162. LAW D, MOORE CB, DENNING DW: Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob. Agents Chemother. (1997) 41:2310-2311.
163. GALGIANI JN, LEWIS ML: In vitro studies of activities of the antifungal triazoles SCH 56592 and itraconazole against Candida albicans, Cryptococcus neoformans and other pathogenic yeasts. Antimicrob. Agents Chemother. (1997) 41:180-183. (Pubitemid 26428152)
164. OAKLEY KL, MOORE CB, DENNING DW: In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob. Agents Chemother. (1997) 41:1124-1126. (Pubitemid 27194196)
165. MARCO F, PFALLER MA, MESSER SA, JONES RN: In vitro activity of a new triazole antifungal agent, SCH 56592, against clinical isolates of filamentous fungi. Mycopa-thologia (1998) 141:73-77. (Pubitemid 28407946)
166. ESPINEL-INGROFF A: Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. (1998) 36:2950-2956. (Pubitemid 28429420)
167. FOTHERGILL AW, SUTTON DA, RINALDI MG: In vitro head-to-head comparison of Schering 56592, amphotericin B, fluconazole and itraconazole against a spectrum of filamentous fungi. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, USA (1996) Abstract F-89.
168. SANCHE SE, FOTHERGILL AW, RINALDI MG: Interspecies variation of the susceptibility of Fusarium species to Schering 56592 in vitro. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract E-66.
169. LOZANO-CHIU M, ARIKAN S, PAETZNICK VL et al.: Treatment of murine fusariosis with SCH 56592. Antimicrob. Agents Chemother. (1999) 43:589-591. (Pubitemid 29109523)
170. PFALLER MA, MESSER S, JONES RN: Activity of a new triazole, Sch 56592, compared with those offour other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimi-crob. Agents Chemother. (1997) 41:233-235. (Pubitemid 27111011)
171. PFALLER MA, MESSER SA, HOLLIS RJet al.: In vitrosusceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, SCH 56592 and voriconazole. Antimicrob. Agents Chemother. (1998) 42:3242-3244. (Pubitemid 28553747)
172. MUNAYYER H, SHAW KJ, HARE RS et al.: SCH 56592 is a potent inhibitor of sterol C14 demethylation in fungi. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, USA (1996) Abstract F-92.
173. FUNG-TOMC JC, HUCZKO E, MINASSIAN B, BONNER DP: In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob. Agents Chemother. (1998) 42:313-318. (Pubitemid 28114437)
174. HATA K, KIMURA J, MIKI H et al.: In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob. Agents Chemother. (1996) 40:2237-2242. (Pubitemid 26328022)
175. HATA K, UNEO J, MIKI H et al.: ER-30346, a novel antifungal triazole: III. In vitro activity and its mode of action. 35th Interscience Conference on antimicrobial Agents and Chemotherapy. San Francisco, USA (1995) Abstract F-92.
176. PATTERSON BE, COATES PE: UK-109,496, a novel, wide spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995):Abstract F-78.
177. PATTERSON BE, ROFFEY S, JEZEQUEL SG, JONES B: UK-109,496,anovel, wide spectrum triazole derivative for the treatment of fungal infections: disposition in man. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995):Abstract F-79.
178. DENNING D, DEL FAVERO A, GLUCKMAN E et al.: UK-109,496,a novel, wide spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995):Abstract F-80.
179. DUPONT B, DENNING D, LODE H et al.: UK-109,496, a novel, wide spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in chronic invasive aspergillosis. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995) Abstract F-81.
180. SCHWARTZ S, MILATOVIC D, THIEL E: Successful treatment of cerebral aspergillosis with novel triazole (voriconazole) in a patient with acute leukemia. Br. J. Haematol. (1997) 97:663-665. (Pubitemid 27261637)
181. JABADO N, CASANOVA JL, HADDAD E et al.: Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulo-matous disease. Clin. Infect. Dis. (1998) 27:1437-1441. (Pubitemid 29242418)
182. HEITMANN L, COMETTA A, HURNI M et al.: Right-sided pacemaker-related endocarditis due to Acremonium species. Clin. Infect. Dis. (1997) 25:158-160. (Pubitemid 27293095)
183. RADWANSKI E, KOSOGLOU T, LIM et al.: SCH56592: bioavailability of an oral suspension relative to a solid dosage form in healthy volunteers. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract A-86.
184. NAKAMURA T, SAKAI R, SONODA J et al.: ER-30346, a novel antifungal triazole: IV. Pharmacokinetics and toxicological studies in mice, rats and dogs. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995) Abstract F-94.
185. HATA K, KIMURA J, MIKI H et al.: Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis and cryptococ-cosis. Antimicrob. Agents Chemother. (1996) 40:2243-2247. (Pubitemid 26328023)
186. LAUGHLIN M, PAI S, MENON S et al.: SCH 56592: rising multiple-dose safety, tolerance and pharmacokinetic evaluation in healthy volunteers. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract A-87.
187. UZUN O, KOCAGOZ S, CETINKAYA Y, ARIKAN S, UNAL S: In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and flucona-zole against clinical yeast isolates. Antimicrob. Agents Chemother. (1997) 41:1156-1157. (Pubitemid 27194204)
188. PFALLER MA, MESSER SA, COFFMAN S: In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivate, LY303366 and other antifungal agents. Antimicrob. Agents Chemother. (1997) 41:763-766. (Pubitemid 27150527)
189. PFALLER MA, MARCO F, MESSER SA, JONES RN: In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus and other filamentous fungi.Diagn. Microbiol. Infect. Dis. (1998) 30:251-255. (Pubitemid 28210124)
190. OAKLEY KL, MOORE CB, DENNING DW: In vitro activity of the echinocandin antifungal agent LY303366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob. Agents Chemother. (1998) 42:2726-2730. (Pubitemid 28462923)
191. VAZQUEZ JA, LYNCH M, BOIKOV D, SOBEL JD: In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and-resistant Candida species. Antimicrob. Agents Chemother. (1997) 41:1612-1614. (Pubitemid 27289700)
192. MARCOF, PFALLER MA, MESSER SA, JONES RN: Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn. Microbiol. Infect. Dis. (1998) 32:33-37. (Pubitemid 29168525)
193. BARTIZAL K, GILL CJ, ABRUZZO GK et al.: In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. (1997) 41:2326-2332. (Pubitemid 27467535)
194. FRANZOT SP, CASADEVALL A: Pneumocandin L-743,872 enhances the activities of amphotericinB and flucona-zole against Cryptococcus neoformans in vitro. Antimicrob. Agents Chemother. (1997) 41:331-336. (Pubitemid 27111027)
195. FOTHERGILL AW, SUTTON DA, RINALDI MG: Antifungal susceptibility testing of Merck L-743,872 against a broad range of fungi. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, USA (1996):Abstract F-29.
196. DEL POETA M, SCHELL WA, PERFECT JR: In vitro antifungal activity ofpneumocandin L-743,872 against a variety of clinically important molds. Antimicrob. Agents Chemother. (1997) 41:1835-1836. (Pubitemid 27339900)
197. MAKI K, MORISHITA Y, IGUCHI Y et al.: In vitro antifungal activity of FK 463, a novel water-soluble echinocandin-like peptide. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998):Abstract F-141.
198. NAKAI T, UNO J, MYAJI M: In vitro activity of FK463, a novel antifungal lipopeptide, against clinically important, less common molds and dimorphic fungi. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1999):Abstract J-1509.
199. LUCAS R, DESANTE K, HATCHER B et al.: LY303366 single dose pharmacokinetics and safety in healthy male volunteers. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, USA (1996):Abstract F-50.
200. RAJMAN I, DESANTE K, HATCHER B et al.: LY303366 single intravenous dose pharmacokinetics and safety in healthy volunteers. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F-74.
201. NI L, SMITH B, HATCHER B et al.: Pharmacokinetics of LY303366 in healthy and HIV-infected volunteers after single-dose oral administration. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998):Abstract J-134.
202. PETRAITIS V, PETRAITIENE R, CANDELARIO M et al.: Efficacy of LY303366, a semisynthetic echinocandin, against fluconazole-resistant esophageal candidiasis. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998):Abstract J-72.
203. PETRAITIENE R, PETRAITIS V, GROLL A et al.: Efficacy of LY303366, a novel echinocandin, against dissemi nated candidiasis in persistently neutropenic rabbits. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998):Abstract J-73.
204. PETRAITIS V, PETRAITIENE R, GROLL AH et al.: Antifungal efficacy, safety and single-dose pharma-cokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. (1998) 42:2898-2905. (Pubitemid 28501223)
205. VERWEIJ PE, OAKLEY KL, MORRISSEY J, MORRISSEY G, DENNING DW: Efficacy of LY303366 against amphotericin B-susceptible and-resistant Aspergillus fumigatus in amurine modelof invasive aspergillosis. Antimicrob. Agents Chemother. (1998) 42:873-878. (Pubitemid 28216370)
206. STONE JA, HOLLAND SD, JU WD et al.: Single-and multiple-dose pharmacokinetics of the antifungal agent MK-0991 in man. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998):Abstract C-51.
207. SABLE CA, VILLANUEVA A, ARATHON E et al.: A randomized, double-blind, multicenter trial of MK-991 (L-743,872) vs. amphotericin B in the treatment of Candida esophagitis in adults. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract LB-33.
208. POWLES MA, LIBERATOR P, ANDERSON J et al.: Efficacy of MK-991 (L-743,872), a semisynthetic pneumo-candin, in murine models of Pneumocystis carinii. Antimicrob. Agents Chemother. (1998) 42:1985-1989. (Pubitemid 28363080)
209. AZUMA J, YAMAMOTO I, OGURA Metal.: PhaseIstudyof FK463, a new antifungal agent, in healthy adult male volunteers. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998) Abstract F-146.
210. PETTENGELL K, MYNHARDT J, KLUYTS S, SONI P: A multicenter study to determine the minimal effective dose of FK463 for the treatment of esophageal candidiasis in HIV-positive patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1999) Abstract J-1421.
211. HIEMENZ J, CAGNONI P, SIMPSON D, DEVINE S, CHAO N: Maximum tolerated dose and pharmacokinetics of FK463 in combination with fluconazole for the prophylaxisoffungal infectionsinadult bone marrow or peripheral stem cell transplant patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1999) Abstract J-1648.
212. SELSTED M, SZKLAREK D, GANZ T, LEHRER R: Activity of rabbit leukocyte peptides against Candida albicans. Infect. Immun. (1985) 49:202-206. (Pubitemid 15062889)
213. ALCOULOUMBRE MS, GHARINOUM MA, IBRAHIM AS, SELSTED ME, EDWARDS JE: Fungicidal properties of defensin NP-1 and activity against Cryptococcus neoformans in vitro. Antimicrob. Agents Chemother. (1993) 37:2628-2632. (Pubitemid 23357858)
214. SEGAL GP, LEHRER RI, SELSTED ME: In vitro effect of phagocyte cationic peptides on Coccidioides immitis. J. Infect. Dis. (1985) 151:890-894. (Pubitemid 15094608)
215. LEVITZ SM, SELSTED ME, GANZ T, LEHRER RI, DIAMOND RD: In vitro killing of spores and hyphae of Aspergillus fumigatus and Rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages. J. Infect. Dis. (1986) 154:483-489. (Pubitemid 16020123)
216. LEHRER RI, GANZ T, SZKLAREK D, SELSTED ME: Modulation of the in situ candidacidal activity of human neutrophil defensins by target cell metabolism and divalent cations. J. Clin. Invest. (1988) 81:1829-1835.
217. GANZ T, SELSTED ME, SZKLAREK Det al.: Natural peptide antibiotics of human neutrophils. J. Clin. Invest. (1985) 76:1427-1435. (Pubitemid 16193690)
218. LAWYER CS, PAL S, WATEBE M et al.: Effects of synthetic form of tracheal antimicrobial peptide on respiratory pathogens. J. Antimicrob. Chemother. (1996) 37:599-604.
219. YAMAUCHI K, TOMITA M, GIEHL TJ, ELLISON RT: Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect. Immun. (1993) 61:719-728. (Pubitemid 23030865)
220. HECTOR RF, ZIMMER BL, PAPPAGIANIS D: Evaluation of nikkomycins X and Z in murine models of cocidioido-mycosis, histoplasmosis, blastomycosis. Antimicrob. Agents Chemother. (1990) 34:587-593. (Pubitemid 20122287)
221. BECKER JM, COVERT NL, SHENBAGAMURTHI P, STEINFELD AS, NAIDER F: PolyoxinDinhibits growth of zoopathogenic fungi. Antimicrob. Agents Chemother. (1983) 23:926-929.
222. GOTTLIEB S, ALTBOUM Z, SAVAGE DC, SEGAL E: Adhesion of Candida albicans to epithelial cells: effect of polyoxin D. Mycopathology (1991) 115:197-216.
223. IWAMOTO T, FUJIIE A, TSURUMI Y, NANBATA K, SHIBUYA K: FR900403, a new antifungal produced by a Kernia spp. J. Antibiotics (1990) 43:1183-1185. (Pubitemid 20324382)